The Mitochondria are the powerhouses of every cell. This is something that we all learned a long time ago in 8th grade biology. However, the story of the role of the mitochondria goes much deeper than just providing power. We know now that the mitochondria may be the cause of a legion of diseases when it malfunctions and restoring the tiny organelle’s behavior with targeted specific drug therapies, may provide truly meaningful new tools for physicians for treating their patients with neurodegenerative diseases and giving hope.
About Mitochon Pharmaceuticals
Mitochon was founded in 2014 with the mission to develop treatments for insidious diseases through the modulation of mitochondrial physiology, with applications to neurodegeneration, neuromuscular, and developmental diseases. Mitochon’s lead programs, MP101 and MP201, specifically harnesses the power of the mitochondria to provide broad neural protection. These compounds elicit mild increases in energy expenditure that result in strengthening cellular survival—similar to the positive effects seen with fasting and exercise. These compounds also induce an important neurotrophin, Brain Derived Neurotrophic Factor (BDNF), involved in cognition and neural growth. Mitochon is supported by Ben Franklin Technology Partners Southeastern PA, an initiative of the Pennsylvania Department of Community and Economic Development funded by the Ben Franklin Technology Development Authority.